Decision Resources will follow AstraZeneca's zibotentan as its proprietary clinical gold standard by 2012. By the year 2017 this gold standard would be used for the treatment of metastatic hormone-refractory prostrate cancer also. Zibotentan  has been chosen over the company’s current gold standard Sanofi-Aventis' Taxotere, due to formers advantages in overall efficacy, safety, tolerability and delivery measures.

Natalia Reoutova, M.Sc., analyst at Decision Resources said, "Interviewed key opinion leaders' optimism for zibotentan's Phase II survival data combined with our survey results make zibotentan the most likely agent to supplant Sanofi-Aventis' Taxotere as our gold standard treatment for metastatic hormone-refractory prostate cancer patients."

Comments

Search RSS

All rights reserved."